BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
Show more...
首席执行官
Mr. Roberto Francesco Bellini
员工
40
国家
加拿大
ISIN
CA07987C2040
WKN
000A2PQKK
上市
0 Comments
分享你的想法
FAQ
Bellus Health 今天的股价是多少?▼
BLU.TO 当前价格为 C$19.48 CAD,在过去 24 小时内下跌了 -0.1%。在图表上更密切关注 Bellus Health 股票的表现。
Bellus Health 的股票代码是什么?▼
根据交易所不同,股票代码可能会有所不同。例如,在 交易所,Bellus Health 的股票以代码 BLU.TO 进行交易。